A British baby’s death this year after getting Novartis’s gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment’s risks.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
For two men trained as scientists, the bosses of Britain’s major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.
Karin E. Bauer, VP, Client Services, at SGK Health, is a passionate advocate for break-through technologies that transform healthcare for the better. She has led in-house and agency brand strategy communications on healthcare products that have moved markets, and maintains strong ties to the research and health technology communities that are driving the future of healthcare. Trained in science and journalism, Karin discovered two developmental cancer therapies before honing her research skills to focus on telling compelling stories about products and organizations that move markets.http://sgkhealth.com